[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
September 12, 2007

Cardiovascular Risk and the ThiazolidinedionesDéjà Vu All Over Again?

Author Affiliations

Author Affiliations: Division of Pharmacoepidemiology (Drs Solomon and Winkelmayer) and Rheumatology, Immunology, and Allergy (Dr Solomon), and Renal Division (Dr Winkelmayer), Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

JAMA. 2007;298(10):1216-1218. doi:10.1001/jama.298.10.1216

In 2005, the US Food and Drug Administration (FDA) held an advisory committee meeting to help determine the safety of selective cyclooxygenase 2 (COX-2) inhibitors, a popular group of drugs with a novel mechanism of action but with incompletely understood effects on the cardiovascular system. Although these drugs have some potential benefits with respect to gastrointestinal toxic effects, their benefit-risk ratio was and is still unclear. Fast forward 2 years to 2007, and the FDA held a similar advisory committee meeting about the safety of rosiglitazone, a widely used thiazolidinedione (TZD) with known benefits on glycemic control but potential cardiovascular toxic effects. What have clinicians, patients, and the public learned through these recent events?

First Page Preview View Large
First page PDF preview
First page PDF preview